{"schema_version":"secwatch.filing_event.v1","accession":"0001013762-23-006952","form_type":"8-K","ticker":"BJDX","cik":"0001704287","company_name":"Bluejay Diagnostics, Inc.","filed_at":"2023-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.109649+00:00","generated_at":"2026-06-09T08:39:32.204645+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bluejay Diagnostics amends Toray license; royalty cut to 7.5% of net sales, supply deal for FDA path","bullets":["Royalty rate reduced from 15% to 7.5% of net sales (or less) for 10-year term; 50% reduction after patent expiry.","New supply agreement: Toray will manufacture intermediates for FDA-approval cartridges through Oct 2025 or FDA clearance.","Bluejay obtains right to sublicense Toray IP to Sanyoseiko for manufacturing Symphony device and cartridges for clinical trials.","Technology transfer from Toray to Sanyoseiko for cartridge manufacturing, enabling commercial scale production.","Prior upfront license fee of $240,000 already paid; post-commercial minimum annual royalty of $100,000."],"urls":{"canonical":"https://secwatch.observer/filing/0001013762-23-006952","json":"https://secwatch.observer/filing/0001013762-23-006952.json","markdown":"https://secwatch.observer/filing/0001013762-23-006952.md","text":"https://secwatch.observer/filing/0001013762-23-006952.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704287/000101376223006952/0001013762-23-006952-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704287/000101376223006952/ea187299-8k_bluejay.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T08:39:32.204645+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b61e78162c1a694a26bc5f16cad1388900f8c1a","claim":"Bluejay Diagnostics, Inc. amended New Toray License Agreement with Toray Industries, Inc. valued at royalty reduced from 15% to 7.5% of net sales (effective 2023-10-23).","evidence_excerpt":"On October 23, 2023, Bluejay Diagnostics, Inc. (the “Company”) and Toray Industries, Inc. (“Toray”) entered into an Amended and Restated License Agreement (the “New Toray License Agreement”) and a Master Supply Agreement (the “New Toray Supply Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000101376223006952/0001013762-23-006952-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Toray Industries, Inc."},{"label":"Value","value":"royalty reduced from 15% to 7.5% of net sales"},{"label":"Effective","value":"2023-10-23"}],"fact_type":"material_agreement"},{"claim_id":"bbc92687a8ffe223d04e9cd180c44a8ccf1eb554","claim":"Bluejay Diagnostics, Inc. amended New Toray Supply Agreement with Toray Industries, Inc. valued at Toray to manufacture near-term product intermediary components for FDA approval, not commercial sale (effective 2023-10-23).","evidence_excerpt":"On October 23, 2023, Bluejay Diagnostics, Inc. (the “Company”) and Toray Industries, Inc. (“Toray”) entered into an Amended and Restated License Agreement (the “New Toray License Agreement”) and a Master Supply Agreement (the “New Toray Supply Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000101376223006952/0001013762-23-006952-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"Toray Industries, Inc."},{"label":"Value","value":"Toray to manufacture near-term product intermediary components for FDA approval, not commercial sale"},{"label":"Effective","value":"2023-10-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}